A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Marker Therapeutics, Inc.
Start Date
April 2, 2018
End Date
May 15, 2020
Administered By
Duke Cancer Institute
Awarded By
Marker Therapeutics, Inc.
Start Date
April 2, 2018
End Date
May 15, 2020